Subscription to La Merie's proprietary Oncology Pipeline Database provides
online access to more than 3,000 project entries in oncology. Each project is
specified for its Target or Mechanism of Action, Product Category and R&D
Phase. Use of the R&D database of cancer drugs is intuitive. Data sets of
interest can be printed and exported. Projects are being updated continuously.
The R&D history of each project with online references of information sources
can be viewed and printed. Sales figures of major products are provided. The
projects can be segmented into Territories, Product Categories and R&D Phases.
An advanced search function allows to combine search parameters. A scroll down
menu for predefined targets conveniently selects projects of interest. By
clicking on column heads of the project list, projects can be arranged in
ascending or descending alphabetical or numerical order, e.g. for phase,
product category or company name.
Sample screenshots illustrate the database.
Purchase of the subscription provides a 1-year online access to the data of
the Oncology Database. Credentials to access the database will be sent by
e-mail within 24 hours after purchase.
Benefits from the Oncology Pipeline Database:
New database with no historical burden
Intuitive use
Designed for structured searches
Focused on targets, product categories and R&D phases
Ideal for competitor analysis (companies, targets, product categories)
Cost-effective and rapid solution for benchmarking
Identification of licensing candidates
Project listing in a tabular format:
Drug Codes
Target / Mechanism of Action
Class of Compound
Product Category
Company
Territory
Therapeutic Area
Indication
R&D Phase
Product Categories:
Antibodies
Cells
DNA
Medical Devicer / Biomaterial
Peptide
Protein
Radiopharmaceutical
RNA
Small Molecule
Vaccine
Predefined Targets of the Scroll Down Menu:
Antibody-Drug Conjugates (ADC)
Aurora Kinase Inhibitors
Bcr-Abl and Src Kinase Inhibitors
c-MET/HGF Inhibitors
CD3 Antagonists
CD19 Antagonists
CD20 Antibodies
CD22 Antibodies
CD30 Antibodies
CD40/L
CEA Antibodies
CHK and KSP/Eg5 Inhibitors
CXCR and CXCL Agonists & Antagonists
Death Receptors TRAIL-R1/2
EGF-R Agonists and Antagonists
EpCAM Antagonists
G-CSF and GM-CSF
HDAC Inhibitors
Heat shock protein 90 (Hsp90) Inhibitors
Hypoxia-Inducible Factor (HIF)
IGF-1R Antagonists
Immunocytokines
Immunotoxins
Integrin Antagonists
Interferon
Janus Kinase (JAK) Inhibitors
MEK Inhibitors
Novel Mitotic Kinase Inhibitors
PARP Inhibitors
PDGF-R Agonists and Antagonists
PI3K-AKT-mTOR Inhibitors
Polo-like Kinase 1 (Plk-1) Inhibitors
Proteasome Inhibitors
Raf Inhibitors
Ras-Raf-MEK-ERK Inhibitors
Selective Estrogen Receptor Modulators (SERM)
TGF-R Agonists and Antagonists
Thrombopoiesis Stimulating Agents (TPO)
Toll-Like Receptor (TLR) Agonists and Antagonists
TRAIL-R1/R2 (Death Receptors)
VEGF and VEGF-R Agonists and Antagonists
Oncology Pipeline Database published by La Merie Publishing in February 3, 2010. This report price starts from US $ 2509.
